---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010931"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T03:56:51.675249+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine reports positive EDIT-301 data; two SCD patients reach normal hemoglobin

## Summary
- Patient 1 (SCD) total hemoglobin 16.4 g/dL at 5 months, maintained at 10-month follow-up; fetal Hb 45.4%.
- Patient 2 (SCD) total hemoglobin 12.7 g/dL at 5 months, fetal Hb 51.3% at 6-month follow-up.
- All four RUBY patients free of vaso-occlusive events post-infusion; no serious adverse events from EDIT-301.
- First EdiTHAL beta thalassemia patient achieved 34.9% fetal Hb (4 g/dL total Hb) at 1.5 months.
- Company on track to dose 20 RUBY patients by year-end; data presented at EHA Congress.

## SEC filing metadata
- accession: 0001558370-23-010931
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837023010931/0001558370-23-010931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837023010931/edit-20230609x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010931
- JSON: https://secwatch.observer/filing/0001558370-23-010931.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.